Abstract
The adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies. © 2012 Springer-Verlag.
Original language | English |
---|---|
Pages (from-to) | 953-962 |
Number of pages | 9 |
Journal | Cancer Immunology, Immunotherapy |
Volume | 61 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2012 |
Keywords
- Cancer
- Chimeric antigen receptor
- Gene modification
- Immunotherapy
- T cell